BioCardia (BCDA) SVP granted 29,442 options and has RSU shares withheld for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioCardia, Inc. Senior Vice President, Devices Edward M. Gillis received a stock option grant and had shares withheld for taxes in a routine compensation-related filing. He was granted options for 29,442 shares of common stock at an exercise price of $1.20 per share, vesting monthly over four years starting August 6, 2026. In a separate transaction, 17,269 common shares were withheld by BioCardia at $1.24 per share to cover income tax obligations on RSUs that vested June 29, 2026, which the company states does not represent a sale by him. Following these transactions, he directly holds 61,139 stock options and 54,126 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
GILLIS EDWARD M
Role
Senior Vice President, Devices
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 29,442 | $0.00 | -- |
| Tax Withholding | Common Stock | 17,269 | $1.24 | $21K |
Holdings After Transaction:
Stock Option (right to buy) — 61,139 shares (Direct, null);
Common Stock — 54,126 shares (Direct, null)
Footnotes (1)
- The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person. The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.
Key Figures
Option grant size: 29,442 options
Option exercise price: $1.20/share
Option expiration: July 6, 2036
+5 more
8 metrics
Option grant size
29,442 options
Stock Option (right to buy) granted on July 6, 2026
Option exercise price
$1.20/share
Exercise price for 29,442 stock options
Option expiration
July 6, 2036
Expiration date of granted stock options
Shares withheld for taxes
17,269 shares
Withheld on July 2, 2026 for RSU tax obligations
Withholding price
$1.24/share
Value used for 17,269 withheld common shares
Post-transaction common shares
54,126 shares
Direct common stock holdings after tax withholding
Post-transaction options
61,139 options
Direct option holdings after option grant
Monthly vesting schedule
1/48th per month
Option vests monthly starting August 6, 2026
Key Terms
RSUs, net settlement, Stock Option (right to buy), tax withholding, +1 more
5 terms
RSUs financial
"the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
net settlement financial
"in connection with the net settlement on July 2, 2026, of the RSUs vested"
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
tax withholding financial
"to satisfy its income tax, withholding and remittance obligations"
Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.
vests and becomes exercisable financial
"The option vests and becomes exercisable as to 1/48th of the shares"
FAQ
What insider transactions did BioCardia (BCDA) disclose for Edward M. Gillis?
BioCardia reported that Senior Vice President, Devices Edward M. Gillis received a stock option grant and had shares withheld for taxes. The filing reflects routine compensation activity rather than open-market buying or selling of BioCardia common stock.
How many BioCardia (BCDA) stock options were granted to Edward M. Gillis?
Edward M. Gillis received options for 29,442 shares of BioCardia common stock at a $1.20 exercise price. The options vest in 1/48th increments monthly, beginning August 6, 2026, contingent on his continued service with the company.
What are Edward M. Gillis’s BioCardia (BCDA) holdings after these transactions?
After the reported transactions, Edward M. Gillis directly holds 54,126 shares of BioCardia common stock and 61,139 stock options. These figures come from the post-transaction ownership totals shown for the common stock and option entries in the Form 4.
How do the new BioCardia (BCDA) options for Edward M. Gillis vest?
The filing states the option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026 and monthly thereafter. Vesting requires Edward M. Gillis to continue as a service provider through each applicable vesting date.